Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database

OBJECTIVE: Weight loss in patients with type 2 diabetes can improve glycemic control, lower blood pressure, and improve dyslipidemia. Glucagon-like peptide (GLP-1) receptor agonists are associated with weight loss and have potentially beneficial effects on cardiovascular risk biomarkers; however, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Horton, Edward S., Silberman, Cheryl, Davis, Keith L., Berria, Rachele
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909058/
https://www.ncbi.nlm.nih.gov/pubmed/20460445
http://dx.doi.org/10.2337/dc09-2062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909058/
https://www.ncbi.nlm.nih.gov/pubmed/20460445
http://dx.doi.org/10.2337/dc09-2062

Ejemplares similares